Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7476802 | 1.00 | TRPV6 (0.46) | TRPV6HRH3LMNAKDM4EABCB1 | |
| SCHEMBL9373487 | 0.84 | HRH3 (0.45) | TRPV6HRH3DRD2HTR1ASLC6A4 | |
| SCHEMBL7477092 | 0.79 | HRH3 (0.54) | TRPV6HRH3DRD2HTR1A | |
| SCHEMBL7477100 | 0.79 | HRH3 (0.54) | TRPV6HRH3DRD2HTR1A | |
| SCHEMBL6984149 | 0.70 | ALDH1A1 (0.51) | SMN1; SMN2 | |
| SCHEMBL9374317 | 0.68 | HRH3 (0.68) | TRPV6HRH3 | |
| SCHEMBL9372055 | 0.68 | HRH3 (0.68) | TRPV6HRH3 | |
| SCHEMBL9372067 | 0.68 | HRH3 (0.68) | TRPV6HRH3 | |
| SCHEMBL12396182 | 0.67 | OPRM1 (0.63) | HRH3KDM4EDRD2HTR1ASMN1; SMN2 | |
| SCHEMBL9372378 | 0.67 | HRH3 (0.65) | TRPV6HRH3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020133004-A1 | Process for producing new oxazepine derivatives | AJINOMOTO CO. INC (JP) | 2002-09-19 | — | — | US | disclosed |
| EP-1219611-A1 | NOVEL PROCESSES FOR PREPARING OXAZEPINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020133004-A1 | Process for producing new oxazepine derivatives | KMO, CYP4B1, GRIN2B | TRPV6 788/4885HRH3 311/4885LMNA 3732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.